文献速递肝病消化道肿瘤与早癌

纳武利尤单抗治疗经索拉非尼治疗的晚期肝细胞癌亚洲队列分析

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
PubMed 文献 · J Hepatol · 2019-06-07

该分析基于CheckMate 040 I/II期研究,纳入经索拉非尼治疗的晚期肝细胞癌患者,比较ITT人群(182例)与亚洲队列(85例)的安全性和疗效。亚洲队列客观缓解率为15%,ITT为14%;中位总生存期分别为14.9个月和15.1个月,安全性特征相似且可控。

要点

  • 亚洲队列客观缓解率15%,与ITT人群14%相近。
  • 亚洲队列中位总生存期14.9个月,与ITT人群15.1个月相似。
  • 亚洲队列中位缓解持续时间9.7个月,短于ITT人群19.4个月。

核心结论

  • 经索拉非尼治疗的晚期肝细胞癌患者中,纳武利尤单抗在ITT人群与亚洲队列的安全性和疗效相当。

研究设计与样本

  • CheckMate 040为国际多中心开放标签I/II期研究(NCT01658878),纳入不可根治性切除或局部治疗的晚期肝细胞癌成人患者,无论病因及既往是否接受索拉非尼治疗。

主要发现

  • ITT人群182例,亚洲队列85例,两组多数患者年龄大于60岁、BCLC C期且接受过既往系统治疗。
  • 亚洲队列HBV感染、肝外转移及既往治疗比例高于ITT人群。
  • ITT与亚洲队列中位随访时间分别为31.6个月和31.3个月。
  • 客观缓解率ITT人群14% vs 亚洲队列15%;亚洲队列中HBV、HCV及未感染患者分别为13%、14%和21%。
  • 中位缓解持续时间ITT人群19.4个月 vs 亚洲队列9.7个月;中位总生存期ITT 15.1个月 vs 亚洲队列14.9个月,亚洲患者中不受病因影响。

临床怎么用

  • 该亚组分析结果支持纳武利尤单抗作为经索拉非尼治疗的晚期肝细胞癌亚洲患者的治疗选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nivolumab, an immune checkpoint inhibitor, is approved in several countries to treat sorafenib-experienced patients with HCC, based on results from the CheckMate 040 study (NCT01658878). Marked differences exist in HCC clinical presentation, aetiology, treatment patterns and outcomes across regions. This analysis assessed the safety and efficacy of nivolumab in the Asian cohort of CheckMate 040. METHODS: CheckMate 040 is an international, multicentre, open-label, phase I/II study of nivolumab in adults with advanced HCC, regardless of aetiology, not amenable to curative resection or local treatment and with/without previous sorafenib treatment. This analysis included all sorafenib-experienced patients in the intent-to-treat (ITT) overall population and Asian cohort. The analysis cut-off date was March 2018. RESULTS: There were 182 and 85 patients in the ITT population and Asian cohort, respectively. In both populations, most patients were older than 60 years, had BCLC (Barcelona Clinic Liver Cancer) Stage C disease, and had received previous systemic therapy. A higher percentage of Asian patients had HBV infections, extrahepatic metastases and prior therapies. Median follow-up was 31.6 and 31.3 months for the ITT and Asian patients, respectively. Objective response rates were 14% and 15% in the ITT population and Asian cohort, respectively. In the Asian cohort, patients with HBV, HCV or those who were uninfected had objective response rates of 13%, 14% and 21%, respectively. The median duration of response was longer in the ITT (19.4 months) vs. Asian patients (9.7 months). Median overall survival was similar between the ITT (15.1 months) and Asian patients (14.9 months), and unaffected by aetiology in Asian patients. The nivolumab safety profile was similar and manageable across both populations. CONCLUSION: Nivolumab safety and efficacy are comparable between sorafenib-experienced ITT and Asian patients. LAY SUMMARY: The CheckMate 040 study evaluated the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma who were refractory to previous sorafenib treatment or chemotherapy. This subanalysis of the data showed that treatment responses and safety in patients in Asia were similar to those of the overall treatment population, providing support for nivolumab as a treatment option for these patients. Clinical trial number: NCT01658878.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yau T, Hsu C, Kim TY, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019. PMID: 31176752. doi:10.1016/j.jhep.2019.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。